S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
Sell every Stock except ONE (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Sell every Stock except ONE (Ad)
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
Sell every Stock except ONE (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Sell every Stock except ONE (Ad)
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
Sell every Stock except ONE (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Sell every Stock except ONE (Ad)
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
Sell every Stock except ONE (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Sell every Stock except ONE (Ad)
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
NASDAQ:ALDX

Aldeyra Therapeutics - ALDX Stock Forecast, Price & News

$5.58
+0.11 (+2.01%)
(As of 10/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.26
$5.60
50-Day Range
$5.00
$7.74
52-Week Range
$2.36
$9.74
Volume
410,664 shs
Average Volume
869,412 shs
Market Capitalization
$325.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.75

Aldeyra Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
240.5% Upside
$19.00 Price Target
Short Interest
Healthy
4.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.18mentions of Aldeyra Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$2.73 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.37) to ($1.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

209th out of 1,072 stocks

Pharmaceutical Preparations Industry

88th out of 534 stocks

ALDX stock logo

About Aldeyra Therapeutics (NASDAQ:ALDX) Stock

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Receive ALDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALDX Stock News Headlines

Why Aldeyra Therapeutics' Shares Are Soaring Today?
See More Headlines
Receive ALDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALDX Company Calendar

Last Earnings
8/05/2022
Today
10/05/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALDX
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+200.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-57,780,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.54 per share

Miscellaneous

Free Float
54,240,000
Market Cap
$325.44 million
Optionable
Optionable
Beta
1.31

Key Executives

  • Todd C. Brady (Age 48)
    M.D., Ph.D., Chief Executive Officer and Director
  • Joshua Reed (Age 47)
    Chief Financial Officer
  • David McMullin (Age 45)
    Chief Commercial Officer
  • James A. Gow (Age 53)
    M.D., Senior Vice President of Clinical Development
  • Stephen G. Machatha (Age 43)
    Ph.D., Senior Vice President, Technical Operation













ALDX Stock - Frequently Asked Questions

Should I buy or sell Aldeyra Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALDX shares.
View ALDX analyst ratings
or view top-rated stocks.

What is Aldeyra Therapeutics' stock price forecast for 2022?

4 brokers have issued 1-year price objectives for Aldeyra Therapeutics' stock. Their ALDX share price forecasts range from $11.00 to $28.00. On average, they expect the company's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 240.5% from the stock's current price.
View analysts price targets for ALDX
or view top-rated stocks among Wall Street analysts.

How have ALDX shares performed in 2022?

Aldeyra Therapeutics' stock was trading at $4.00 at the beginning of 2022. Since then, ALDX shares have increased by 39.5% and is now trading at $5.58.
View the best growth stocks for 2022 here
.

When is Aldeyra Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our ALDX earnings forecast
.

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) announced its quarterly earnings data on Friday, August, 5th. The biotechnology company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.02.

What other stocks do shareholders of Aldeyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), KushCo (KSHB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), Novan (NOVN), OrganiGram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

What is Aldeyra Therapeutics' stock symbol?

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aldeyra Therapeutics' stock price today?

One share of ALDX stock can currently be purchased for approximately $5.58.

How much money does Aldeyra Therapeutics make?

Aldeyra Therapeutics (NASDAQ:ALDX) has a market capitalization of $325.44 million. The biotechnology company earns $-57,780,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis.

How can I contact Aldeyra Therapeutics?

Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The official website for the company is www.ampliphibio.com. The biotechnology company can be reached via phone at 781-761-4904, via email at ir@ampliphibio.com, or via fax at 781-270-0630.

This page (NASDAQ:ALDX) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.